Orthofix Medical (NasdaqGS:OFIX) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsJulie Andrews - CFOJulie Dewey - Chief Investor Relations and Communications OfficerMassimo Calafiore - President and CEOMathew Blackman - Managing DirectorMichaela Smith - Equity Research AssociateTom Stephan - AVPConference Call ParticipantsMike Petusky - Managing Director and Senior Research AnalystOperatorThank you. I would now like to turn the call over to Julie Dewey.Julie DeweyThank you, operator, ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the "Company†or "Allurion†), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the "January 2025 Warrants†), February 20, 2025 (the "February 2025 Warrants†) and November 12, 2025 (the "November 2025 Wa. ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsCaitlin Roberts - DirectorJayson Bedford - Managing DirectorJens Schoener - CMOLindsey Hartley - CFOMichael Dale - CEORick Ditto - Medical Device & Life Science ExecutiveSimran Kaur - VPConference Call ParticipantsAnthony Petrone - Managing Director, Senior Medical Devices, Diagnostics and Therapeutics Equity Research AnalystChris Pasquale - Senior AnalystFrank Takkinen - Senior Research AnalystMichael Sarcone - A ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAnthony Petrone - Managing DirectorCaitlin Roberts - DirectorJayson Bedford - Managing DirectorJens Schoener - CMOLindsey Hartley - CFOMichael Dale - CEORick Ditto - Medical Device & Life Science ExecutiveSimran Kaur - VPConference Call ParticipantsChris Pasquale - Senior AnalystFrank Takkinen - Senior Research AnalystMichael Sarcone - AnalystMike Kratky - AnalystOperatorGood morning, everyone. Joining me on today ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker9Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director, and Lindsey Hartley, Chief Financial Officer. Michael will discuss fourth quarter and full year 2025 financial results and corporate highlights. Lindsey will then provide details on financial performance, guidance, and overall outlook for the year. This will be followed by a question-and-answer session. Today's c ...

Getting patients back to what matters. Dave Pacitti Chief Executive Officer Q4/FY Overview & Business Update Q4 & Full Year 2025 Earnings Presentation February 24, 2026 Scott Galovan SVP, Chief Financial Officer Q4/FY Results & 2026 Planning Assumptions DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, ...

we use and rely on, to the movies and games that inspire us. Autodesk's Design and Make Platform unlocks the power of data to accelerate insights and automate processes, empowering our customers with the technology to create the world around us and deliver better outcomes for their business and the planet. For more information, visit autodesk.com or follow @autodesk. #MakeAnythingAutodesk and others are registered trademarks of Autodesk, Inc., and/or its subsidiaries and/or affiliates in the USA and/or othe ...

Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced RoboticsHINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company’s recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance ...

Achieved record 2025 revenue of $201 million, driven by a 22% increase in U.S. physician adoption and expanded utilization across the sacropelvic platform. Transitioned to a sustainable financial profile, delivering the first full year of positive adjusted EBITDA and reaching positive free cash flow in the fourth quarter. Leveraged a hybrid sales model to drive territory productivity to $2.1 million per manager, an 18% year-over-year increase. Strengthened market leadership in the thoracolumbar spac ...

TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the Company’s patent application titled “Feeding Tube with Electromagnetic Sensor and Camera,” Application No. 18/199,059. The allowed patent includes 18 claims covering a feeding tube design that combines ...